Profound Medical will present the TULSA Procedure in four oral sessions at the American Urological Association’s Annual Meeting on May 16 in Washington, DC. Sessions cover MRI characteristics linked to treatment outcomes, morphologic and perfusion changes from neoadjuvant therapies, and 12-month safety and efficacy data from phase 2 trials. Attendees can visit booth #413 for live demonstrations of the TULSA-PRO system paired with a Siemens MAGNETOM Free.Max MR unit. This showcase aims to reinforce the procedure’s real-time imaging and precision ablation benefits.

Profound has launched an initiative to integrate PSMA PET molecular imaging into its TULSA-PRO treatment planning software. This integration is designed to help clinicians better define prostate lesions, set precise ablation margins, and monitor treatment response. By combining PET’s molecular sensitivity with MRI’s anatomical detail, the company seeks to deliver more personalized, intent-to-treat therapies across focal, subtotal, and whole-gland approaches. Development work is underway to embed PSMA PET data directly into the software interface for streamlined planning.

The integration project underscores Profound’s strategy to expand its iMRI platform capabilities and address multifocal prostate cancer in which 85% of cases involve multiple lesions. Executives believe enhanced imaging fusion will differentiate TULSA-PRO in a competitive ablation market and support broader clinical adoption. Demonstrations at AUA2026 aim to drive physician engagement and generate pre-commercial interest ahead of future software releases. Success could position Profound for stronger procedure volumes and recurring software licensing revenue.